The DEEP project has received research funding from the European Union under the 7th Framework Programme

News

The ApoPharma point of view: interview to Dr. Michael Spino

Marzo 25, 2016
|
Comments off
|

The DEEP Project has already brought forth its first results and is continuing along the challenging path of a large multinational clinical trial. At this point, which is now in the final stage, we asked Dr. Michale Spino, President of ApoPharma Inc. to describe the major contribution provided […]

Share
Read more →

Performing a paediatric clinical study in Tunisia: interview to Prof. Mohamed Bejaoui

Marzo 25, 2016
|
Comments off
|

Paediatric trials have a default level of complexity, that is depending on regulatory, methodological, ethical and administrative issues, especially when they are registrative and international as DEEP-2 is.

DEEP-2 is, in fact, a multi-national and multi-center clinical trial involving not only a paediatric multi […]

Share
Read more →

7th DEEP General Assembly meeting in Padua (Italy)

Marzo 25, 2016
|
Comments off
|

After the sad decision to cancel the General Assembly Meeting in Tunis, due to the disorders which have occurred across the country, the 7th DEEP General Assembly (GA) will take place in Padua (Italy) on April 13th -15th, 2016 with the participation of the whole DEEP […]

Share
Read more →

DEEP-2: almost at the final rush

Marzo 25, 2016
|
Comments off
|

Another step forward has been made toward the enrollment of new patients in the DEEP-2 study, the phase III multicentre, randomised, open label, non-inferiority active-controlled trial aiming at comparing for the first time the efficacy of deferiprone (DFP) vs deferasirox (DFX) in paediatric patients affected […]

Share
Read more →